Adjuvant trastuzumab in early breast cancer
Open Access
- 1 September 2006
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 17 (suppl_10) , x54-x58
Abstract
G. Mariani, L. Gianni; Adjuvant trastuzumab in early breast cancer, Annals of Oncology, Volume 17, Issue suppl_10, 1 September 2006, Pages x54–x58, https://doiKeywords
This publication has 23 references indexed in Scilit:
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort studyBMJ, 2005
- Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast CancerJNCI: Journal of the National Cancer Institute, 2004
- Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance AlgorithmJournal of Clinical Oncology, 2003
- Phase II Trial of Gemcitabine plus Trastuzumab in Metastatic Breast Cancer Patients Previously Treated with Chemotherapy: Preliminary ResultsClinical Breast Cancer, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998